Global Cannabis-based Medicines Market Growth (Status and Outlook) 2023-2029

Global Cannabis-based Medicines Market Growth (Status and Outlook) 2023-2029

Marijuana (medical cannabis) is used to treat nausea, pain, anxiety, MS, insomnia, epilepsy, and other conditions. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main chemicals used in medicine. In the medicines market, Epidiolex, the first cannabis-based medication approved by the US Food and Drug Administration.

LPI (LP Information)' newest research report, the “Cannabis-based Medicines Industry Forecast” looks at past sales and reviews total world Cannabis-based Medicines sales in 2022, providing a comprehensive analysis by region and market sector of projected Cannabis-based Medicines sales for 2023 through 2029. With Cannabis-based Medicines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cannabis-based Medicines industry.

This Insight Report provides a comprehensive analysis of the global Cannabis-based Medicines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cannabis-based Medicines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cannabis-based Medicines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cannabis-based Medicines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cannabis-based Medicines.

The global Cannabis-based Medicines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cannabis-based Medicines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cannabis-based Medicines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cannabis-based Medicines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cannabis-based Medicines players cover GW Pharmaceuticals plc, INSYS Therapeutics, Aequus Pharmaceuticals, Axim Biotechnologies, Revive Therapeutics, MGC Pharmaceuticals and ECHO Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cannabis-based Medicines market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
CBD (Cannabidiol) Based
THC (Tetrahydrocannabinol) Based
Others

Segmentation by application
Oral Solution
Tablets
Patches
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GW Pharmaceuticals plc
INSYS Therapeutics
Aequus Pharmaceuticals
Axim Biotechnologies
Revive Therapeutics
MGC Pharmaceuticals
ECHO Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.